Natco Pharma Limited is a research-oriented pharmaceutical company specializing in generic medicines, oncology products, active pharmaceutical ingredients (APIs), and specialty pharmaceuticals. Founded in 1981, the company has built a strong reputation for developing complex generics, niche formulations, and affordable alternatives to high-cost medicines. Natco serves more than 50 countries through strategic partnerships and direct commercial operations, with particular strength in oncology, hepatology, cardiology, and central nervous system therapies. The company is widely recognized for successfully challenging patents and introducing cost-effective medicines that improve patient access globally. Natco operates advanced manufacturing facilities approved by major international regulatory agencies, supporting exports to regulated markets such as the United States, Europe, and Canada. Continued investment in research and development, intellectual property capabilities, and product innovation has enabled Natco to establish a differentiated position within the global pharmaceutical industry while maintaining its commitment to affordable healthcare.
NSE: NATCOPHARM | BSE: 524816
Hyderabad, Telangana, India
~5,000 employees
